(Q42602739)

3 November 2017

title

The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study (English)

1 reference

3 November 2017

1 reference

3

1 reference

3 November 2017

4

Ferrendelli J

1 reference

3 November 2017

Morrell MJ

1

1 reference

3 November 2017

Leppik I

series ordinal

2

1 reference

3 November 2017

Han J

series ordinal

5

1 reference

3 November 2017

Magnus L

series ordinal

6

1 reference

3 November 2017

publication date

1 May 2003

1 reference

3 November 2017

1 reference

3 November 2017

volume

54

1 reference

3 November 2017

issue

2-3

1 reference

3 November 2017

page(s)

153-161

1 reference

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

Absence of Pharmacokinetic Drug Interaction of Levetiracetam with Phenytoin in Patients with Epilepsy Determined by New Technique

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

Long-term continuation of levetiracetam in patients with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900080-9

7 January 2021

10.1016/S0920-1211(03)00080-9

Identifiers

DOI

1 reference

3 November 2017

1 reference